These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 30592773)

  • 21. Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.
    Meulendijks D; Henricks LM; Jacobs BAW; Aliev A; Deenen MJ; de Vries N; Rosing H; van Werkhoven E; de Boer A; Beijnen JH; Mandigers CMPW; Soesan M; Cats A; Schellens JHM
    Br J Cancer; 2017 May; 116(11):1415-1424. PubMed ID: 28427087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Severe fluoropyrimidine-related toxicity: clinical implications of DPYD analysis and UH2/U ratio evaluation.
    Giorgio E; Caroti C; Mattioli F; Uliana V; Parodi MI; D'Amico M; Fucile C; Marini V; Forzano F; Cassola G; Martelli A; Faravelli F; Di Maria E
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1355-61. PubMed ID: 21833589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Relationship between dihydropyrimidine dehydrogenase(DPD) activity and toxicity of 5-FU-based adjuvant chemotherapy in colorectal cancer patients].
    Zhou ZW; Wang GQ; Wan DS; Pan ZZ; Li S; Chen G; Liao H
    Ai Zheng; 2004 Nov; 23(11 Suppl):1512-6. PubMed ID: 15566669
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phenotypic and clinical implications of variants in the dihydropyrimidine dehydrogenase gene.
    Kuilenburg ABPV; Meijer J; Tanck MWT; Dobritzsch D; Zoetekouw L; Dekkers LL; Roelofsen J; Meinsma R; Wymenga M; Kulik W; Büchel B; Hennekam RCM; Largiadèr CR
    Biochim Biophys Acta; 2016 Apr; 1862(4):754-762. PubMed ID: 26804652
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of an oral uracil loading test to identify DPD-deficient patients using a limited sampling strategy.
    van Staveren MC; van Kuilenburg AB; Guchelaar HJ; Meijer J; Punt CJ; de Jong RS; Gelderblom H; Maring JG
    Br J Clin Pharmacol; 2016 Mar; 81(3):553-61. PubMed ID: 26551538
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy.
    Ciccolini J; Mercier C; Evrard A; Dahan L; Boyer JC; Duffaud F; Richard K; Blanquicett C; Milano G; Blesius A; Durand A; Seitz JF; Favre R; Lacarelle B
    Ther Drug Monit; 2006 Oct; 28(5):678-85. PubMed ID: 17038885
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil.
    Mattison LK; Fourie J; Hirao Y; Koga T; Desmond RA; King JR; Shimizu T; Diasio RB
    Clin Cancer Res; 2006 Jan; 12(2):549-55. PubMed ID: 16428499
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy.
    Wettergren Y; Carlsson G; Odin E; Gustavsson B
    Cancer; 2012 Jun; 118(11):2935-43. PubMed ID: 22020693
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency.
    Pallet N; Hamdane S; Garinet S; Blons H; Zaanan A; Paillaud E; Taieb J; Laprevote O; Loriot MA; Narjoz C
    Br J Cancer; 2020 Sep; 123(5):811-818. PubMed ID: 32595208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lethal toxicities after capecitabine intake in a previously 5-FU-treated patient: why dose matters with dihydropryimidine dehydrogenase deficiency.
    Gbeto CC; Quaranta S; Mari R; Fanciullino R; Roche C; Nahon S; Solas C; Ouafik L; Lacarelle B; Allegre T; Ciccolini J
    Pharmacogenomics; 2019 Aug; 20(13):931-938. PubMed ID: 31486738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Issues and limitations of available biomarkers for fluoropyrimidine-based chemotherapy toxicity, a narrative review of the literature.
    Hodroj K; Barthelemy D; Lega JC; Grenet G; Gagnieu MC; Walter T; Guitton J; Payen-Gay L
    ESMO Open; 2021 Jun; 6(3):100125. PubMed ID: 33895696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endogenous plasma and salivary uracil to dihydrouracil ratios and DPYD genotyping as predictors of severe fluoropyrimidine toxicity in patients with gastrointestinal malignancies.
    Galarza AF; Linden R; Antunes MV; Hahn RZ; Raymundo S; da Silva AC; Staggemeier R; Spilki FR; Schwartsmann G
    Clin Biochem; 2016 Nov; 49(16-17):1221-1226. PubMed ID: 27399164
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients.
    Zhou ZW; Wang GQ; Wan de S; Lu ZH; Chen YB; Li S; Chen G; Pan ZZ
    Chemotherapy; 2007; 53(2):127-31. PubMed ID: 17308379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. LC-MS/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients.
    Büchel B; Rhyn P; Schürch S; Bühr C; Amstutz U; Largiadèr CR
    Biomed Chromatogr; 2013 Jan; 27(1):7-16. PubMed ID: 22454320
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients.
    van Staveren MC; Opdam F; Guchelaar HJ; van Kuilenburg AB; Maring JG; Gelderblom H
    Cancer Chemother Pharmacol; 2015 Jul; 76(1):47-52. PubMed ID: 25957957
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of liver resection on the dihydrouracil:uracil plasma ratio in patients with colorectal liver metastases.
    Jacobs BAW; Snoeren N; Samim M; Rosing H; de Vries N; Deenen MJ; Beijnen JH; Schellens JHM; Koopman M; van Hillegersberg R
    Eur J Clin Pharmacol; 2018 Jun; 74(6):737-744. PubMed ID: 29430582
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 5-Fluorouracil Response Prediction and Blood Level-Guided Therapy in Oncology: Existing Evidence Fundamentally Supports Instigation.
    Chavani O
    Ther Drug Monit; 2020 Oct; 42(5):660-664. PubMed ID: 32649488
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved analysis of 5-Fluorouracil and 5,6-dihydro-5-Fluorouracil by HPLC with diode array detection for determination of cellular dihydropyrimidine dehydrogenase activity and pharmacokinetic profiling.
    Di Paolo A; Danesi R; Ciofi L; Vannozzi F; Bocci G; Lastella M; Amatori F; Martelloni BM; Ibrahim T; Amadori D; Falcone A; Del Tacca M
    Ther Drug Monit; 2005 Jun; 27(3):362-8. PubMed ID: 15905808
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
    Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
    Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Determination of Endogenous Concentrations of Uracil and Dihydrouracil in Dried Saliva Spots by LC-MS/MS: Method Development, Validation, and Clinical Application.
    Antunes MV; Raymundo S; Cezimbra da Silva AC; Muller VV; Vicente Neto OJ; Schwartsmann G; Linden R
    Ther Drug Monit; 2019 Jun; 41(3):383-390. PubMed ID: 30807536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.